Is a single dose of ChAdOx1 nCoV‐19 vaccine (AZD1222) enough for people with prior SARS‐CoV‐2 infection or baseline seropositive status?. (October 2022)

• Record Type: Journal Article
• Authors: Deswal, Vikas; Phogat, Rashmi; Sharma, Pooja; Kataria, Sushila; Soin, Arvinder
• Is Part Of: International journal of infectious diseases. Volume 123(2022)
• Page Start: 143
• Page End: 144
• Publication Date: 2022-10
• Subjects: Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2022.06.051
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: Better IgG responses were observed in baseline seropositive individuals. Single-dose IgG responses to AZD1222 were better in indviduals who were previously infected with COVID. One dose may be sufficient for individuals who were previously infected with COVID.